Abstract 5291
Background
The Irish Longitudinal Study on Ageing (TILDA) estimates that 13.1% of the Irish population is vitamin D3 deficient, compared with less than 6% of the US population surveyed in the National Health and Nutrition Examination Survey (NHANES). In recent years, numerous studies have shed light on a potential role for vitamin D3 in breast cancer risk modification and prognosis. We set out to assess the prevalence and clinical significance of vitamin D3 deficiency in women with breast cancer receiving chemotherapy in an Irish oncology dayward.
Methods
Retrospective chart review was conducted to collect data incuding patient age, cancer stage at diagnosis, date of treatment initiation and 25-hydroxy vitamin D3 (25(OH)D3) levels at start of treatment. Vitamin D3 deficiency was defined as a value <50 nmol/L. Charlson Comorbidity Index (CCI) was caluclated for all patients. Mean 25(OH)D3 levels by season (autumn, winter, spring, summer) were also caluclated. As the data set was not normally distributed, inter-group comparison was conducted using the Kruskal-Wallis Test with p < 0.05 considered significant.
Results
41 women had available baseline 25(OH)D3 levels and were included. 66% were deficient in 25(OH)D3 at baseline. The prevalence of vitamin D3 deficiency showed substantial seasonal variation, being highest in the winter months (88%) and lowest in the summer months (0%). Furthermore, mean 25(OH)D3 levels were lowest in the winter months (29.0nmol/L + 13.8) and highest in the summer months (66.3nmol/L + 11.5). The difference in mean 25(OH)D3 levels across the four seasons was significant (p = 0.022). Women who were deficient in vitamin D3 tended to be younger (p = 0.00001), have a higher cancer stage (p = 0.0071), and have a less favorable 10-year all cause mortality risk as indicated by their CCI (p = 0.0041).
Conclusions
We found a striking prevalence of 25(OH)D3 deficiency among women with breast cancer receiving adjuvant/neoadjuvant chemotherapy in an Irish oncology dayward. Notable seasonal variation in mean vitamin D3 levels was observed. Vitamin D3 deficiency was found to be more prevalent in younger women and was associated with a higher stage of breast cancer as well as a less favorable 10-year all cause mortality risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4250 - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
Presenter: Erika Martinelli
Session: Poster Display session 2
Resources:
Abstract
5234 - The ORCHESTRA trial; A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).
Presenter: Lotte Bakkerus
Session: Poster Display session 2
Resources:
Abstract
5294 - EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal cancers
Presenter: Elizabeth Cartwright
Session: Poster Display session 2
Resources:
Abstract
913 - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): subgroup analyses
Presenter: Margaret Tempero
Session: Poster Display session 2
Resources:
Abstract
1668 - FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma : update of the AGEO cohort.
Presenter: Edouard Auclin
Session: Poster Display session 2
Resources:
Abstract
2559 - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT)
Presenter: Hanno Riess
Session: Poster Display session 2
Resources:
Abstract
4897 - Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumor DNA
Presenter: Xiao-ding Liu
Session: Poster Display session 2
Resources:
Abstract
1755 - Evaluation of minimal important difference (MID) for the European Organisation for Research and Treatment of Cancer (EORTC) Pancreatic Cancer Module (PAN26) in patients with surgically resected pancreatic adenocarcinoma
Presenter: Michele Reni
Session: Poster Display session 2
Resources:
Abstract
2876 - Multispectral analysis of lymphocyte complexity in periampullary adenocarcinoma
Presenter: Sebastian Lundgren
Session: Poster Display session 2
Resources:
Abstract
1902 - Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Jae Ho Jeong
Session: Poster Display session 2
Resources:
Abstract